Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

TP ICAP buys bond market data provider Neptune Networks

(Sharecast News) - TP ICAP said on Monday that it has bought Neptune Networks, an independent financial data company co-owned by a consortium of investment banks, for an undisclosed sum. Neptune delivers high-quality, real-time pre-trade bond market data from many sell-side banks to buy-side clients, the interdealer broker said.

"TP ICAP will bring together Neptune's extensive proprietary data network with Liquidnet's electronic credit trading platform, creating a unique, full service, global Dealer-to-Client (D2C) credit business," it said.

At launch, Barclays, BNP Paribas, Citi, Credit Agricole CIB, Deutsche Bank, ING, JP Morgan, Morgan Stanley and UBS - the bank shareholders - will own a 30% stake in the new business.

TP ICAP said this ownership structure is intended to ensure that Liquidnet and the bank shareholders are "resourced and incentivised to grow the business".

Chief executive Nicolas Bretea said: "Neptune is an exceptional platform with deep connectivity on both the sell-side and buy-side. With our partners, we plan to enhance and grow Neptune's core data business, strengthening its relevance to the buy-side via Liquidnet's electronic credit trading platform.

"By combining Liquidnet's extensive client reach with leading liquidity providers, we can seamlessly and discreetly connect the sell-side and buy-side to unlock exciting potential, positioning us well to drive a step-change in fixed income markets and liquidity."

Broker Peel Hunt, which rates TP ICAP at 'buy' with a 337p price target, said: "While no financial details were disclosed, we assume the transaction is small in the context of the group, but it should support the growth of the D2C credit platform in the coming years."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.